Iovance Biotherapeutics, Inc. $IOVA Shares Sold by American Century Companies Inc.

American Century Companies Inc. decreased its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 80.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 24,974 shares of the biotechnology company's stock after selling 101,680 shares during the quarter. American Century Companies Inc.'s holdings in Iovance Biotherapeutics were worth $83,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Nuveen LLC acquired a new position in shares of Iovance Biotherapeutics during the first quarter valued at $2,953,000. Invesco Ltd. grew its position in Iovance Biotherapeutics by 50.6% in the 1st quarter. Invesco Ltd. now owns 334,257 shares of the biotechnology company's stock worth $1,113,000 after purchasing an additional 112,329 shares during the last quarter. Chicago Partners Investment Group LLC grew its position in Iovance Biotherapeutics by 97.6% in the 1st quarter. Chicago Partners Investment Group LLC now owns 40,626 shares of the biotechnology company's stock worth $127,000 after purchasing an additional 20,067 shares during the last quarter. CM Management LLC grew its position in Iovance Biotherapeutics by 66.7% in the 1st quarter. CM Management LLC now owns 500,000 shares of the biotechnology company's stock worth $1,665,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Iovance Biotherapeutics by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 27,777,778 shares of the biotechnology company's stock worth $92,500,000 after purchasing an additional 243,438 shares during the last quarter. Institutional investors and hedge funds own 77.03% of the company's stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. Wells Fargo & Company decreased their target price on shares of Iovance Biotherapeutics from $18.00 to $14.00 and set an "overweight" rating for the company in a research report on Friday, August 8th. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Iovance Biotherapeutics in a research report on Tuesday, August 19th. Chardan Capital reduced their price objective on shares of Iovance Biotherapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a report on Friday, August 8th. The Goldman Sachs Group downgraded shares of Iovance Biotherapeutics from a "neutral" rating to a "sell" rating in a report on Tuesday, July 15th. Finally, UBS Group downgraded shares of Iovance Biotherapeutics from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $17.00 to $2.00 in a report on Friday, May 16th. Six research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $11.90.

Iovance Biotherapeutics Stock Performance

NASDAQ IOVA traded up $0.01 on Wednesday, reaching $2.38. The company's stock had a trading volume of 11,173,761 shares, compared to its average volume of 13,565,511. Iovance Biotherapeutics, Inc. has a twelve month low of $1.64 and a twelve month high of $12.51. The stock has a market cap of $861.20 million, a PE ratio of -1.93 and a beta of 0.82. The firm's 50 day moving average is $2.41 and its two-hundred day moving average is $2.72.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.04). Iovance Biotherapeutics had a negative net margin of 161.44% and a negative return on equity of 52.87%. The business had revenue of $59.95 million for the quarter, compared to analyst estimates of $67.14 million. Iovance Biotherapeutics has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Iovance Biotherapeutics, Inc. will post -1.24 EPS for the current fiscal year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.